Author/Creator: Raz, I. - British Library Electronic Legal Deposit Catalogue-Journal Issues and Articles Search Results

Author/Creator Raz, I.

1. Achieving the composite endpoint of glycated haemoglobin <7.0%, no weight gain and no hypoglycaemia in the once‐weekly dulaglutide AWARD programme. Issue 1 (3rd November 2015)

Authors:: Dungan, K. M.; Raz, I.; Skrivanek, Z.; Sealls, W.; Fahrbach, J. L.
Journal:: Diabetes, obesity & metabolism
Issue:: Volume 18:Issue 1(2016)
Page Start:: 49
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

2. Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)‐TIMI 53 trial1. Issue 5 (21st May 2013)

Authors:: Mosenzon, O.; Raz, I.; Scirica, B. M.; Hirshberg, B.; Stahre, C. I.; Steg, P. G.; Davidson, J.; Ohman, P.; Price, D. L.; Frederich, B.; Udell, J. A.; Braunwald, E.; Bhatt, D. L.
Journal:: Diabetes/metabolism research and reviews
Issue:: Volume 29:Issue 5(2013:Jul.)
Page Start:: 417
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

3. Frequency of cancer events with saxagliptin in the SAVOR‐TIMI 53 trial. Issue 2 (27th November 2015)

Authors:: Leiter, L. A.; Teoh, H.; Mosenzon, O.; Cahn, A.; Hirshberg, B.; Stahre, C. A. M.; Hoekstra, J. B. L.; Alvarsson, M.; Im, K.; Scirica, B. M.; Bhatt, D. L.; Raz, I.
Journal:: Diabetes, obesity & metabolism
Issue:: Volume 18:Issue 2(2016)
Page Start:: 186
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

4. Impact of treatment with saxagliptin on glycaemic stability and β‐cell function in the SAVOR‐TIMI 53 study. Issue 5 (25th February 2015)

Authors:: Leibowitz, G.; Cahn, A.; Bhatt, D. L.; Hirshberg, B.; Mosenzon, O.; Wei, C.; Jermendy, G.; Sheu, W. H.‐H.; Sendon, J. L.; Im, K.; Braunwald, E.; Scirica, B. M.; Raz, I.
Journal:: Diabetes, obesity & metabolism
Issue:: Volume 17:Issue 5(2015:May)
Page Start:: 487
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

5. LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial. Issue 1 (December 2016)

Authors:: Masmiquel, L.; Leiter, L.; Vidal, J.; Bain, S.; Petrie, J.; Franek, E.; Raz, I.; Comlekci, A.; Jacob, S.; Gaal, L.; Baeres, F.; Marso, S.; Eriksson, M.
Journal:: Cardiovascular diabetology
Issue:: Volume 15:Issue 1(2016)
Page Start:: 1
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

6. Response to: 'baseline differences in SAVOR trial' – prespecified vs. post hoc analysis – a potential source of bias. Issue 12 (December 2015)

Authors:: Raz, I.; Cahn, A.; Mosenzon, O.; Scirica, B. M.; Bhatt, D. L.
Journal:: Diabetes, obesity & metabolism
Issue:: Volume 17:Issue 12(2015:Dec.)
Page Start:: 1203
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

7. The Barmer study: impact of standardized warming of the injection site to enhance insulin absorption and reduce prandial insulin requirements and hypoglycemia in obese patients with diabetes mellitus. (May 2014)

Authors:: Pfützner, A.; Hermanns, N.; Funke, K.; Forst, T.; Behnke, T.; Bitton, G.; Nagar, R.; Raz, I.; Haak, T.
Journal:: Current medical research and opinion
Issue:: Volume 30:Number 5(2014:May)
Page Start:: 753
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗